Company overview
Informuta develops precision diagnostics for drug-resistant infections using machine learning and DNA sequencing technology. The company's RESISENSE platform forecasts treatment-emergent antibiotic resistance before it occurs, enabling clinicians to select optimal therapies on a patient-by-patient basis. Informuta's technology helps prevent treatment failures, reduce antibiotic misuse, and strengthen antimicrobial stewardship in hospital settings.
AI-Powered Antibiotic Resistance Diagnostics is listed in the NovaPharmaNews Supplier Hub as a CRO & Clinical Services, Diagnostics & Testing partner serving United States & Americas. Core focus areas include antibiotic resistance diagnostics, machine learning genomics, drug susceptibility testing, precision infectious disease, antimicrobial stewardship.
Industry categories: CRO & Clinical Services, Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Products and technologies associated with AI-Powered Antibiotic Resistance Diagnostics include Cro, Diagnostic — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://www.informuta.com
- Categories
- CRO & Clinical Services, Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- antibiotic resistance diagnostics, machine learning genomics, drug susceptibility testing, precision infectious disease, antimicrobial stewardship
Products & technologies
Therapeutic areas
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What is Informuta's core diagnostic technology?
- Informuta's RESISENSE platform combines AI and DNA sequencing to analyze bacterial infections for current antibiotic susceptibilities and predict the likelihood of resistance development during treatment. The technology can forecast resistance probability at specific timepoints (7, 30, 90 days) to guide clinical decision-making.
- What regulatory certifications is Informuta pursuing?
- Informuta is working toward Clinical Laboratory Improvement Amendments (CLIA) certification for its clinical laboratory at the New Orleans BioInnovation Center, which will enable validated diagnostic reporting for direct patient care impact.
- Which bacterial pathogens does Informuta's technology address?
- While initial research focused on Pseudomonas aeruginosa (a CDC-designated serious resistance threat), Informuta's technology is broadly applicable to virtually all medically important and difficult-to-treat bacteria.
- What is Informuta's implementation timeline for clinical use?
- Informuta is targeting its first full implementation pilot by the end of 2026, with plans for 24-hour turnaround results integrated into real-time treatment protocols, initially through partnership with Ochsner Health.
- How does Informuta's approach differ from traditional diagnostics?
- Traditional diagnostics provide a snapshot of current drug susceptibility. Informuta adds predictive capability by forecasting how bacterial resistance will evolve over the course of treatment, enabling proactive therapeutic selection rather than reactive adjustments.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
